ClinicalTrials.gg
CompletedNCT03535870Updated Nov 29, 2019

Clinical Endpoint Bioequivalence Study of Fluticasone Propionate & Salmeterol Xinafoate (100μg/50μg)

An interventional study of Fluticasone propionate/salmeterol and Advair Diskus, 100 Mcg-50 Mcg Inhalation Powder in Asthma, sponsored by West-Ward Pharmaceutical. Completed at 1 site in United States. Open to participants aged 12 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-11-29.

Sponsored by West-Ward Pharmaceutical (part of Hikma Pharmaceuticals) · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,556
Allocation
Randomized
Ages
12 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 147 studies testing fluticasone in Asthma — 1 open to participants now, 4 under way, 2 of them phase 3. Fluticasone · Asthma.

Enrollment
4th of 146
1,556 · median 100
Started
2018
with 5 others
No phase
13 of 147
none open now
Registered
131st of 147
by date

Among the 147 studies testing fluticasone in Asthma, this one is the 4th largest by enrollment of the 146 interventional ones that give a count, is one of 6 that started in 2018, is one of 13 with no phase, and was the 131st registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

1 of the 147 studies testing fluticasone in Asthma is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About fluticasone

Fluticasone: first FDA approval 1990 (CUTIVATE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 12 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 147 studies testing fluticasone in Asthma, or all of them as a file.
02

Study summary

A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 μg and Salmeterol Xinafoate 50 μg Inhalation Powder Compared with Advair Diskus® 100/50 in Subjects with Asthma

Read the detailed description

The primary objective of this study is to evaluate the clinical bioequivalence of generic fluticasone propionate 100 μg and salmeterol xinafoate 50 μg inhalation powder (test) to Advair Diskus ("Advair") 100/50 (reference) for the treatment of asthma.

The secondary objectives of the study are:

  • To demonstrate statistical superiority of generic fluticasone propionate 100 μg and salmeterol xinafoate 50 μg inhalation powder to placebo.
  • To demonstrate statistical superiority of Advair 100/50 to placebo.
  • To investigate the safety and tolerability of fluticasone propionate 100 μg and salmeterol xinafoate 50 μg inhalation powder compared with Advair 100/50 in the target population
03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
12 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female subjects must be 12 years of age or older.
  2. Females must not be of or if of childbearing potential, must commit to consistent use of a form of which is medically effective, in the judgment of the investigator.
  3. Be able to provide written or, in the case of adolescents, informed assent in addition to an informed consent form (ICF) signed by the adolescent's parent(s) or legal guardian(s).
  4. Be current non-smokers and also may not have used tobacco products (e.g., cigarettes, e-cigarettes, cigars, pipe tobacco) within the year prior to Visit 1, and have 10 years or less (10 pack-years for cigarettes) of historical use.
  5. Have persistent asthma, as defined by the National Asthma Education and Prevention Program, for at least 12 weeks before Visit 1.
  6. at Visit 1 (screening) and Visit 2 (randomization) of: ≥40% and ≤85% predicted normal value (for age ≥18 years), or ≥65% and ≤85% predicted normal value (for ages 12 to 17 years)
  7. Demonstrate ≥15% reversibility of FEV1 between 10 and 30 minutes following 360 μg of albuterol inhalation. This may be demonstrated at the Screening Visit or anytime in the period leading up to Visit 2 (randomization).
  8. Be able to discontinue controller asthma medication (including LTM, inhaled [ICS] and long-acting β-agonists (LABAs]) during the Run-in Period and Treatment Period.
  9. Be able to replace current short-acting β-agonists (SABAs) with the study-supplied albuterol (or equivalent) rescue medication inhaler for use as needed for the duration of the study (subjects should be able to withhold all inhaled SABAs for a least 6 hours before lung function assessments during study visits).
  10. Must not have been treated (for any reason) with oral or parenteral corticosteroids for at least 1 month before Visit 1 and must not have used oral SABAs (not inhaled) for at least 12 hours before Visit 1 and for the remainder of the study. Use of oral/parenteral corticosteroids and oral SABAs is prohibited after Visit 1.
  11. Subjects may continue using short-acting forms of theophylline (withheld at least 12 hours before study visits), twice daily controlled-release forms of theophylline (withheld at least 24 hours before study visits), and once daily controlled-release forms of theophylline (withheld at least 36 hours before study visits). Subjects must be judged by the investigator as able to withhold these medications for the specified minimum time intervals before each site visit.
  12. Be able to answer questions regarding asthma status and be able to document device usage and asthma status on a twice daily basis.
  13. Demonstrate proper use of MDI and dry-powder inhaler devices.

Exclusion criteria

Exclusion Criteria:

  1. Have a reversibility of \<15% at Visit 1.
  2. Are unable to discontinue ICS, LABA, or LTM.
  3. Have a history of life-threatening asthma, defined as an asthma episode (at any time in the past) associated with any of the following: respiratory arrest or intubation, hypercapnia, hypoxic seizures, or syncopal episode.
  4. Have a hospitalization within the year prior to Screening due to an asthma exacerbation.
  5. Have exercise-induced asthma as the only asthma-related diagnosis that does not require daily asthma control medicine.
  6. Have evidence or history of congestive heart failure, uncontrolled hypertension, uncontrolled coronary artery disease, myocardial infarction, or cardiac dysrhythmia.
  7. Have evidence or history of any disease (hematologic, hepatic, neurologic, psychiatric, renal, or other) that in the opinion of the investigator, would put the subject at risk through study participation, or would affect the study analyses if the disease exacerbated during the study.
  8. Have any other relevant pulmonary disease except for asthma, including but not limited to (COPD), interstitial lung disease, cystic fibrosis, bronchiectasis, chronic bronchitis, emphysema, active pulmonary tuberculosis, pulmonary carcinoma, pulmonary fibrosis, or pulmonary hypertension.
  9. Have obstructive sleep apnea severe enough to warrant a prescription for biphasic or continuous positive-airway pressure therapy (BiPAP or CPAP), regardless of subject compliance with this therapy.
  10. Taking any of the following medications:

    • Oral or parenteral beta blockers (excluding eye drops)
    • Strong cytochrome P450 3A4 inhibitors
    • Anti-IgE therapy, Xolair (omalizumab)
    • Monoamine oxidase (MAO) Inhibitors
    • Monoclonal antibodies/biologic agents which may affect the course of asthma (such as mepolizumab, reslizumab, lebrizumab, and others)
  11. Had a viral or bacterial, upper or lower respiratory tract infection or sinus or middle ear infection within 4 weeks before Screening (Visit 1), or have such an infection during the Run-in Period.
  12. Participated in an interventional study or used any drug for any disease within 30 days (or 5 half-lives, if this is longer than 30 days) before Visit 1, or participated in this interventional study under the current protocol at any time previously.
  13. Are hypersensitive to any β2-agonist sympathomimetic drug, or any intranasal, inhaled, or systemic therapy or any component of these combination medications including severe milk protein .
  14. Are exhibiting any factors (e.g., infirmity, disability, or geographic location, inability to follow instructions or study compliance requirements) that the investigator believes would likely limit the subject's compliance with the study protocol or scheduled site visits.
  15. Have an affiliation with the participating site; in other words, subject may not be an immediate family member of any study site staff and may not be employed directly or indirectly by the study site.
  16. Have a positive urine drug screen at Screening Visit.
  17. Have a positive urine cotinine screen at Screening Visit.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,556 participants (actual)

Study arms

  • Experimental
    Fluticasone propionate/salmeterol

    fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) twice a day by inhalation throughout the study

    Drug: Fluticasone propionate/salmeterol

  • Active comparator
    Advair Diskus, 100 Mcg-50 Mcg Inhalation Powder

    Advair Diskus (fluticasone propionate and salmeterol xinafoate) twice a day by inhalation throughout the study

    Drug: Advair Diskus, 100 Mcg-50 Mcg Inhalation Powder

  • Placebo comparator
    Placebo

    placebo inhaled powder twice a day by inhalation throughout the study

    Drug: Placebo

Interventions

  • DrugFluticasone propionate/salmeterol

    Drug pages: Fluticasone · Salmeterol Xinafoate

    Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered via the LOMI inhaler device

  • DrugAdvair Diskus, 100 Mcg-50 Mcg Inhalation Powder

    Advair (Fixed dose combination of fluticasone propionate and salmeterol xinafoate administered via the Diskus inhaler device)

  • DrugPlacebo

    placebo dry powder administered via the LOMI inhaler device

06

What researchers measure

Primary outcomes

  1. FEV1-time curve (day 1)

    Baseline-adjusted area under the serial FEV1-time curve calculated from time 0 (zero) to 12 hours on the first day of the Treatment Period

    Time frame: 24 hours

  2. FEV1-time curve (day 28)

    Baseline-adjusted, pre-dose FEV1 on the last day of the Treatment Period

    Time frame: 24 hours

07

Study locations

1 site
  • West-Ward Research Site #1
    Las Vegas, Nevada 89119, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2018 to primary completion in Sep 2019, 16 months.

Of 50 industry-sponsored interventional studies with no phase under Asthma, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 24. This study's 16 months is above that.

Counting every sponsor, half of 649 studies reached it within 23 months; a quarter within 10 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2018
First posted
May 24, 2018
StartActual
Apr 26, 2018
Primary completionActual
Sep 10, 2019
CompletionActual
Sep 10, 2019
Last update
Nov 29, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 29, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03535870
Responsible party
Sponsor
First posted
May 24, 2018
Start date
Apr 26, 2018
Primary completion
Sep 10, 2019
Completion
Sep 10, 2019
Last update
Nov 29, 2019

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fluticasone · Salmeterol Xinafoate

Start the discussion